Cell cycle, CDKs and cancer: a changing paradigm.

Article Details


Malumbres M, Barbacid M

Cell cycle, CDKs and cancer: a changing paradigm.

Nat Rev Cancer. 2009 Mar;9(3):153-66. doi: 10.1038/nrc2602.

PubMed ID
19238148 [ View in PubMed

Tumour-associated cell cycle defects are often mediated by alterations in cyclin-dependent kinase (CDK) activity. Misregulated CDKs induce unscheduled proliferation as well as genomic and chromosomal instability. According to current models, mammalian CDKs are essential for driving each cell cycle phase, so therapeutic strategies that block CDK activity are unlikely to selectively target tumour cells. However, recent genetic evidence has revealed that, whereas CDK1 is required for the cell cycle, interphase CDKs are only essential for proliferation of specialized cells. Emerging evidence suggests that tumour cells may also require specific interphase CDKs for proliferation. Thus, selective CDK inhibition may provide therapeutic benefit against certain human neoplasias.

DrugBank Data that Cites this Article

NameUniProt ID
Cyclin-dependent-like kinase 5Q00535Details
Cyclin-dependent kinase 2P24941Details
Cyclin-dependent kinase 1P06493Details
Cyclin-dependent kinase 7P50613Details
Cyclin-dependent kinase 9P50750Details
Cyclin-dependent kinase 6Q00534Details